TY - JOUR T1 - MHC Haplotyping of SARS-CoV-2 patients: HLA subtypes are not associated with the presence and severity of Covid-19 in the Israeli population JF - medRxiv DO - 10.1101/2020.12.23.20248148 SP - 2020.12.23.20248148 AU - Shay Ben Shachar AU - Noam Barda AU - Sigal Manor AU - Sapir Israeli AU - Noa Dagan AU - Shai Carmi AU - Ran Balicer AU - Bracha Zisser AU - Yoram Louzoun Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/12/26/2020.12.23.20248148.abstract N2 - HLA haplotypes were found to be associated with increased risk for viral infections or disease severity in various diseases, including SARS. Several genetic variants are associated with Covid-19 severity. However, no clear association between HLA and Covid-19 incidence or severity has been reported. We conducted a large scale HLA analysis of Israeli individuals who tested positive for SARS-CoV-2 infection by PCR. Overall, 72,912 individuals with known HLA haplotypes were included in the study, of whom 6,413 (8.8%) were found to have SARS-CoV-2 by PCR. a Total of 20,937 subjects were of Ashkenazi origin (at least 2/4 grandparents). One hundred eighty-one patients (2.8% of the infected) were hospitalized due to the disease. None of the 66 most common HLA loci (within the five HLA subgroups; A, B, C, DQB1, DRB1) was found to be associated with SARS-CoV-2 infection or hospitalization. Similarly, no association was detected in the Ashkenazi Jewish subset. Moreover, no association was found between heterozygosity in any of the HLA loci and either infection or hospitalization.We conclude that HLA haplotypes are not a major risk/protecting factor among the Israeli population for SARS-CoV-2 infection or severity.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis is a retrospective studyFunding StatementNo external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was performed with the approval of the Institutional Research Community (IRB) #0080-20-COM2) of Clalit Health Care. The aproving IRB committee was of the Community section of Cllait's HMO, located at Tel-Aviv Israel. The chair of the Commmittee was Prof. Jacob Hart. The saproval was signed on September 21th 2020 All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be available upon request ER -